Zimmer Biomet price target raised to $155 from $149 at Baird

Baird analyst Jeff Johnson raised the firm’s price target on Zimmer Biomet to $155 from $149 and keeps an Outperform rating on the shares. The firm said its end markets are firming, commercial execution is improving, and now, with a new $200M cost-savings program, the path to consistent double-digit EPS growth seems to be clearing.